Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer to present data on new Alzheimer’s treatments

Pfizer to present data on new Alzheimer’s treatments

9th July 2010

Pfizer has announced plans to detail the clinical progress of a number of treatments in its Alzheimer’s portfolio at an upcoming medical conference.

The company is to attend the Alzheimer’s Association International Conference on Alzheimer’s Disease 2010 (ICAD 2010) in Honolulu over the next week in order to present more than 40 abstracts on various compounds.

These will include its beta amyloid passive immunotherapy programme, which it has developed in collaboration with Janssen Alzheimer Immunotherapy, as well as data from PDE inhibition and 5-HT(6) receptor antagonism studies.

In addition, the company will also address attendees on a number of other issues affecting Alzheimer’s patients, including comorbidities and the burden of care and costs.

Steve Romano, vice-president and medical affairs head of Pfizer’s primary care business unit, said: “The breadth of data being presented at ICAD 2010 highlights Pfizer’s strategic approach to the discovery and development of potential new medicines.”

Last month, Pfizer announced that it will be creating a new business unit dedicated to research into rare diseases, in order to help address unmet global medical needs.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.